Are sodium‐glucose cotransporter‐2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

Bibliographic Details
Main Authors:	Mohamad Ahangar Davoodi, Mohammad Ali Daneshmand, Taraneh Rezaei
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
by: Jincheng Shen, et al.
Published: (2025)

Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
by: Chinatsu Sakai, et al.
Published: (2025)

Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
by: Keiko Maruyama‐Sakurai, et al.
Published: (2024)

Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
by: Tasuku Imada, et al.
Published: (2024)

Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
by: Ryo Suzuki, et al.
Published: (2025)

Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
by: Hsiao‐Wei Wang, et al.
Published: (2025)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
by: Shunichiro Tsukamoto, et al.
Published: (2024)

Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
by: Kyoung Hwa Ha, et al.
Published: (2024)

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
by: Jingchuan Guo, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
by: Andy Bowe, et al.
Published: (2025)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
by: Juliana de Oliveira Costa, et al.
Published: (2024)

The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression
by: Yen‐Chen Chiu, et al.
Published: (2025)

Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium–glucose cotransporter‐2 inhibitor therapy: A multicentre database analysis in Taiwan
by: Yu‐Wen Cheng, et al.
Published: (2024)

Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
by: Hiroaki Iijima, et al.
Published: (2024)

Comment on “The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression”
by: Shyam Sundar Sah, et al.
Published: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
by: Sama M. Abdel‐Rahman, et al.
Published: (2026)

Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter ‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial
by: Min Yang, et al.
Published: (2024)

The association between sodium glucose cotransporter‐2 inhibitors vs dipeptidyl peptidase‐4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population‐based cohort study
by: Kate E. D. Ziser, et al.
Published: (2024)

Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study)
by: Ayako Shigeta, et al.
Published: (2025)

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
by: Alex E. Henney, et al.
Published: (2024)

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
by: Afif Nakhleh, et al.
Published: (2024)

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study
by: Kazuya Hiura, et al.
Published: (2026)

Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice
by: Miriam Longo, et al.
Published: (2024)

Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes
by: Shujun Zhang, et al.
Published: (2024)

Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
by: Angelica Sharma, et al.
Published: (2025)

Risk of recurrent diabetic ketoacidosis following initiation of sodium‐glucose co‐transporter 2 inhibitors in patients with an insulin‐deficient diabetes and prior diabetic ketoacidosis: An observational cohort study
by: Anat Tsur, et al.
Published: (2026)

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
by: Paschalis Karakasis, et al.
Published: (2024)

Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
by: Hui‐Lin Sung, et al.
Published: (2024)

An estimate of the need for continuous glucose monitoring in type 2 diabetes with intensive insulin treatment in secondary healthcare
by: Christian Trolle, et al.
Published: (2024)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
by: Donna Shu‐Han Lin, et al.
Published: (2024)

Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
by: Sibylle de Germay, et al.
Published: (2024)

Effects of insulin‐induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes
by: Therese Wilbek Fabricius, et al.
Published: (2025)

Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?
by: Kowalczyk‐Korcz Emilia, et al.
Published: (2026)

Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes
by: Atsushi Kitamura, et al.
Published: (2024)

Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database
by: Tomohiko Kanaoka, et al.
Published: (2024)

Long‐term blood glucose control via glucose‐activated transcriptional regulation of insulin analogue in type 1 diabetes mice
by: Wanling Lu, et al.
Published: (2025)

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study
by: Yuta Nakamura, et al.
Published: (2024)

Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis
by: Qiufeng Jia, et al.
Published: (2024)

The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
by: Leonardo Buttice, et al.
Published: (2024)

Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus
by: SophieAnne Buckley, et al.
Published: (2024)

Similar Items

Similar Items